Expansion into intravascular lithotripsy (IVL) strengthens cardiovascular portfolio.
Boston Scientific has successfully finalized its acquisition of Bolt Medical, a move that expands its capabilities in the treatment of coronary and peripheral artery disease. This acquisition follows the FDA’s recent 510(k) clearance of the Bolt IVL system, which was granted on March 25, 2025, just two months after its submission.
Strengthening the Cardiovascular Portfolio
- Strategic Investment: Boston Scientific initially helped develop the concept for Bolt’s IVL technology, which uses acoustic pressure waves to treat calcified lesions in coronary and peripheral arteries.
- Acquisition Details: The acquisition is valued at $600 million upfront, with up to an additional $300 million tied to regulatory milestones.
The Competitive IVL Landscape
Boston Scientific enters a competitive IVL space, joining Shockwave Medical, Abbott, and other rising players like FastWave Medical, Vantis Vascular, and Amplitude Vascular. The growing interest in IVL highlights its potential to transform treatment for calcified arterial disease.
Bolt Medical’s Innovative Technology
- Laser-based IVL: Bolt’s technology uses a balloon catheter to create acoustic pressure waves that fracture calcium in arteries.
- Visible Energy Delivery: Its directional emitters ensure consistent and accurate energy application during treatment.
With this acquisition, Boston Scientific is poised to expand its cardiovascular offerings, positioning itself as a key player in the growing IVL market.
Follow MEDWIRE.AI for more updates on MedTech acquisitions and innovations.
